On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3 clinical trial had begun to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who had mild or moderate COVID-19.

The two experimental antibodies, BRII-196 and BRII-198, target SARS-CoV-2, the virus that causes COVID-19. The tria was sponsored in part by the National Institutes of Health.